Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors. - Shimizu T; Powderly J; Abdul Razak A; LoRusso P; Miller KD; Kao S; Kongpachith S; Tribouley C; Graham M; Stoll B; Patel M; Sahtout M; et al. (Frontiers in oncology, 2025)